These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 29684975)
1. [Novel Palliative Chemotherapy in Patients with Metastatic Pancreatic Cancer: PEGPH20]. Kim DU Korean J Gastroenterol; 2018 Apr; 71(4):244-245. PubMed ID: 29684975 [No Abstract] [Full Text] [Related]
2. HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma. Hingorani SR; Zheng L; Bullock AJ; Seery TE; Harris WP; Sigal DS; Braiteh F; Ritch PS; Zalupski MM; Bahary N; Oberstein PE; Wang-Gillam A; Wu W; Chondros D; Jiang P; Khelifa S; Pu J; Aldrich C; Hendifar AE J Clin Oncol; 2018 Feb; 36(4):359-366. PubMed ID: 29232172 [TBL] [Abstract][Full Text] [Related]
3. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma. Van Cutsem E; Tempero MA; Sigal D; Oh DY; Fazio N; Macarulla T; Hitre E; Hammel P; Hendifar AE; Bates SE; Li CP; Hingorani SR; de la Fouchardiere C; Kasi A; Heinemann V; Maraveyas A; Bahary N; Layos L; Sahai V; Zheng L; Lacy J; Park JO; Portales F; Oberstein P; Wu W; Chondros D; Bullock AJ; J Clin Oncol; 2020 Sep; 38(27):3185-3194. PubMed ID: 32706635 [TBL] [Abstract][Full Text] [Related]
4. Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy. Portal A; Pernot S; Siauve N; Landi B; Lepère C; Colussi O; Rougier P; Zaanan A; Verrière B; Taieb J Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):e23-6. PubMed ID: 24559766 [TBL] [Abstract][Full Text] [Related]
5. Combination chemotherapy with gemcitabine and nab-paclitaxel for a metastatic pancreatic ductal adenocarcinoma patient undergoing hemodialysis. Kaneko T; Sugimori K; Tozuka Y; Fukushima T; Okada K; Oka H; Okazaki H; Maeda S Clin J Gastroenterol; 2019 Oct; 12(5):484-489. PubMed ID: 30993653 [TBL] [Abstract][Full Text] [Related]
6. Real-World Clinical Practice of Intensified Chemotherapies for Metastatic Pancreatic Cancer: Results from a Pan-European Questionnaire Study. Le N; Vinci A; Schober M; Krug S; Javed MA; Kohlmann T; Sund M; Neesse A; Beyer G Digestion; 2016; 94(4):222-229. PubMed ID: 28030863 [TBL] [Abstract][Full Text] [Related]
7. PEGPH20 May Improve Standard-of-Care Therapy in Pancreatic Cancer. Cancer Discov; 2018 Feb; 8(2):136. PubMed ID: 29269345 [TBL] [Abstract][Full Text] [Related]
9. Implementation of contemporary chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma: a population-based analysis. Latenstein AEJ; Mackay TM; Creemers GJ; van Eijck CHJ; de Groot JWB; Haj Mohammad N; Homs MYV; van Laarhoven HWM; Molenaar IQ; Ten Tije BJ; de Vos-Geelen J; Besselink MG; van der Geest LGM; Wilmink JW; Acta Oncol; 2020 Jun; 59(6):705-712. PubMed ID: 32056483 [No Abstract] [Full Text] [Related]
10. Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial. Reni M; Zanon S; Peretti U; Chiaravalli M; Barone D; Pircher C; Balzano G; Macchini M; Romi S; Gritti E; Mazza E; Nicoletti R; Doglioni C; Falconi M; Gianni L Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):691-697. PubMed ID: 30220407 [TBL] [Abstract][Full Text] [Related]
11. Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis. Riedl JM; Posch F; Horvath L; Gantschnigg A; Renneberg F; Schwarzenbacher E; Moik F; Barth DA; Rossmann CH; Stotz M; Schaberl-Moser R; Pichler M; Stöger H; Greil R; Djanani A; Schlick K; Gerger A Eur J Cancer; 2021 Jul; 151():3-13. PubMed ID: 33951545 [TBL] [Abstract][Full Text] [Related]
12. Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer. Hingorani SR; Harris WP; Beck JT; Berdov BA; Wagner SA; Pshevlotsky EM; Tjulandin SA; Gladkov OA; Holcombe RF; Korn R; Raghunand N; Dychter S; Jiang P; Shepard HM; Devoe CE Clin Cancer Res; 2016 Jun; 22(12):2848-54. PubMed ID: 26813359 [TBL] [Abstract][Full Text] [Related]
13. Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study. Zong Y; Yuan J; Peng Z; Lu M; Wang X; Shen L; Zhou J J Cancer Res Clin Oncol; 2021 May; 147(5):1529-1536. PubMed ID: 33191450 [TBL] [Abstract][Full Text] [Related]
14. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study. Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161 [TBL] [Abstract][Full Text] [Related]
15. Phase I/II Study: Experience with the Late Onset of Acute Pancreatitis after the Start of Chemotherapy with Gemcitabine Plus nab-Paclitaxel for Metastatic Pancreatic Cancer. Ueno M; Nagashima F; Ueno H; Ikeda M; Ohkawa S; Mizuno N; Ioka T; Omuro Y; Nakajima TE; Furuse J Intern Med; 2019 Oct; 58(20):2957-2962. PubMed ID: 31243233 [TBL] [Abstract][Full Text] [Related]
16. Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry. Santucci J; Tacey M; Thomson B; Michael M; Wong R; Shapiro J; Jennens R; Clarke K; Pattison S; Burge M; Zielinski R; Nikfarjam M; Ananda S; Lipton L; Gibbs P; Lee B Eur J Cancer; 2022 Oct; 174():102-112. PubMed ID: 35988408 [TBL] [Abstract][Full Text] [Related]
17. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Perri G; Prakash L; Qiao W; Varadhachary GR; Wolff R; Fogelman D; Overman M; Pant S; Javle M; Koay EJ; Herman J; Kim M; Ikoma N; Tzeng CW; Lee JE; Katz MHG JAMA Surg; 2020 Sep; 155(9):832-839. PubMed ID: 32667641 [TBL] [Abstract][Full Text] [Related]
18. Drug interactions: the importance of looking inside cancer cells. Clark JW Cancer Discov; 2012 Mar; 2(3):208-10. PubMed ID: 22585991 [TBL] [Abstract][Full Text] [Related]
19. Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma. Noel M; O'Reilly EM; Wolpin BM; Ryan DP; Bullock AJ; Britten CD; Linehan DC; Belt BA; Gamelin EC; Ganguly B; Yin D; Joh T; Jacobs IA; Taylor CT; Lowery MA Invest New Drugs; 2020 Jun; 38(3):800-811. PubMed ID: 31297636 [TBL] [Abstract][Full Text] [Related]
20. Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2. Macarulla T; Pazo-Cid R; Guillén-Ponce C; López R; Vera R; Reboredo M; Muñoz Martin A; Rivera F; Díaz Beveridge R; La Casta A; Martín Valadés J; Martínez-Galán J; Ales I; Sastre J; Perea S; Hidalgo M J Clin Oncol; 2019 Jan; 37(3):230-238. PubMed ID: 30523758 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]